Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Immunol Rev. 2010 Jan;233(1):126-45. doi: 10.1111/j.0105-2896.2009.00863.x.
The U1 small nuclear ribonucleoprotein particle (snRNP) is a target of autoreactive B cells and T cells in several rheumatic diseases including systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). We propose that inherent structural properties of this autoantigen complex, including common RNA-binding motifs, B and T-cell epitopes, and a unique stimulatory RNA molecule, underlie its susceptibility as a target of the autoimmune response. Immune mechanisms that may contribute to overall U1-snRNP immunogenicity include epitope spreading through B and T-cell interactions, apoptosis-induced modifications, and toll-like receptor (TLR) activation through stimulation by U1-snRNA. We conclude that understanding the interactions between U1-snRNP and the immune system will provide insights into why certain patients develop anti-U1-snRNP autoimmunity, and more importantly how to effectively target therapies against this autoimmune response.
U1 小核核糖核蛋白颗粒(snRNP)是几种风湿性疾病(包括系统性红斑狼疮[SLE]和混合性结缔组织病[MCTD])中自身反应性 B 细胞和 T 细胞的靶标。我们提出,该自身抗原复合物的固有结构特性,包括常见的 RNA 结合基序、B 细胞和 T 细胞表位以及独特的刺激 RNA 分子,是其作为自身免疫反应靶标的基础。可能有助于 U1-snRNP 免疫原性的免疫机制包括通过 B 和 T 细胞相互作用产生的表位扩展、凋亡诱导的修饰以及通过 U1-snRNA 刺激激活 Toll 样受体(TLR)。我们得出结论,了解 U1-snRNP 与免疫系统之间的相互作用将深入了解为什么某些患者会产生抗 U1-snRNP 自身免疫,更重要的是如何有效地针对这种自身免疫反应进行靶向治疗。